Susquehanna Fundamental Investments’s NovoCure NVCR Stock Holding History

Susquehanna Fundamental Investments’s Portfolio NVCR Stock Details NVCR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q3	–	Sell	-116,362	Closed	-$2.07M	–	705
2025 Q2	$2.07M	Sell	116,362 -53,984	-32%	-$941K	0.06%	330
2025 Q1	$3.04M	Buy	+170,346	New	+$3.87M	0.04%	426
2023 Q2	–	Sell	-5,865	Closed	-$353K	–	805
2023 Q1	$353K	Sell	5,865 -46,401	-89%	-$3.71M	0.01%	756
2022 Q4	$3.83M	Buy	52,266 +7,561	+17%	+$569K	0.07%	350
2022 Q3	$3.4M	Buy	+44,705	New	+$3.49M	0.06%	430
2022 Q1	$6.72M	Buy	81,151 +40,869	+101%	+$3.01M	0.13%	222
2021 Q4	$3.02M	Buy	40,282 +6,624	+20%	+$665K	0.08%	311
2021 Q3	$3.91M	Buy	33,658 +21,513	+177%	+$3.25M	0.07%	370
2021 Q2	$2.69M	Buy	+12,145	New	+$2.36M	0.05%	499

Other funds holding NVCR

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

SCM

Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return

QCM

Quantinno Capital Management New York $59.9B AUM 28.07% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Susquehanna Fundamental Investments's NVCR Position: Q3 2025 in Review

Susquehanna Fundamental Investments sold out of NovoCure (NVCR) in Q3 2025, closing a stake of 116,362 shares — an estimated $2.07M sold.

Susquehanna Fundamental Investments first reported a position in NVCR in Q2 2021 and held it in 9 quarters. The position peaked at $6.72M in Q1 2022. 245 funds tracked by Wall St. Rank hold NVCR as of Q3 2025.

Susquehanna Fundamental Investments reported no remaining NovoCure position as of Q3 2025 after selling out during the quarter.
Susquehanna Fundamental Investments sold 116,362 NovoCure shares in Q3 2025, an estimated $2.07M.
Susquehanna Fundamental Investments first reported a position in NovoCure in Q2 2021 and held it in 9 quarters.
Susquehanna Fundamental Investments's NovoCure position peaked at $6.72M in Q1 2022.
245 funds tracked by Wall St. Rank held NovoCure as of Q3 2025.

Based on Susquehanna Fundamental Investments's 13F filing for Q3 2025, filed 14 Nov 2025.